I am sure that per patient cost includes all prior overhead and any other failed trials.
A while back I ran across a statement that the average approved drug cost, roughly, $1B to develop. Take a look at the Anavex website for its accrued deficit. Compare that to the expected further development cost for Rett and for AD, and you will appreciate Missling's financial stewardship.
Market Data 
Markets 
AI
